[go: up one dir, main page]

MX2023013078A - Anticuerpos de inmunorreceptor de celulas t con dominios ig e itim (anti-tigit), anticuerpos de cumulo de diferenciacion 96 (anti-cd96) y metodos de uso de estos. - Google Patents

Anticuerpos de inmunorreceptor de celulas t con dominios ig e itim (anti-tigit), anticuerpos de cumulo de diferenciacion 96 (anti-cd96) y metodos de uso de estos.

Info

Publication number
MX2023013078A
MX2023013078A MX2023013078A MX2023013078A MX2023013078A MX 2023013078 A MX2023013078 A MX 2023013078A MX 2023013078 A MX2023013078 A MX 2023013078A MX 2023013078 A MX2023013078 A MX 2023013078A MX 2023013078 A MX2023013078 A MX 2023013078A
Authority
MX
Mexico
Prior art keywords
antibodies
tigit
multispecific molecules
methods
human
Prior art date
Application number
MX2023013078A
Other languages
English (en)
Inventor
Benjamin Maxime Morin
Dhan Sidhartha Chand
Olga Ignatovich
Nicola Anne Ramsay
K Mark Bushell
Emmanuel Cyrille Pascal Briend
Zahra Jawad
Veronica Franciszka Ilkow
Beth Wensley
Spencer Campbell
Original Assignee
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc filed Critical Agenus Inc
Publication of MX2023013078A publication Critical patent/MX2023013078A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripción proporciona moléculas multiespecíficas que se unen específicamente a CD96 (por ejemplo, CD96 humano) y/o TIGIT (por ejemplo, TIGIT humano) y anticuerpos aislados que se unen específicamente a TIGIT (por ejemplo, TIGIT humano). También se proporcionan composiciones farmacéuticas que comprenden estas moléculas y anticuerpos multiespecíficos, ácidos nucleicos que codifican estas moléculas y anticuerpos multiespecíficos, vectores de expresión y células hospederas para preparar estas moléculas y anticuerpos multiespecíficos, y métodos para tratar a un sujeto mediante el uso de estas moléculas y anticuerpos multiespecíficos.
MX2023013078A 2021-05-04 2022-05-04 Anticuerpos de inmunorreceptor de celulas t con dominios ig e itim (anti-tigit), anticuerpos de cumulo de diferenciacion 96 (anti-cd96) y metodos de uso de estos. MX2023013078A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163201537P 2021-05-04 2021-05-04
PCT/US2022/072099 WO2022236276A2 (en) 2021-05-04 2022-05-04 Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2023013078A true MX2023013078A (es) 2023-11-16

Family

ID=83933041

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013078A MX2023013078A (es) 2021-05-04 2022-05-04 Anticuerpos de inmunorreceptor de celulas t con dominios ig e itim (anti-tigit), anticuerpos de cumulo de diferenciacion 96 (anti-cd96) y metodos de uso de estos.

Country Status (16)

Country Link
US (2) US11718669B2 (es)
EP (1) EP4333893A4 (es)
JP (1) JP2024516843A (es)
KR (1) KR20240006054A (es)
CN (1) CN117425494A (es)
AR (1) AR125753A1 (es)
AU (1) AU2022271331A1 (es)
BR (1) BR112023022319A2 (es)
CA (1) CA3217289A1 (es)
CL (1) CL2023003244A1 (es)
CO (1) CO2023016037A2 (es)
IL (1) IL308157A (es)
MX (1) MX2023013078A (es)
PE (1) PE20240369A1 (es)
TW (1) TW202304965A (es)
WO (1) WO2022236276A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202304965A (zh) 2021-05-04 2023-02-01 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法
WO2025188697A1 (en) * 2024-03-04 2025-09-12 Agenus Inc. Methods of treating cancer using anti-cd96/anti-tigit antibodies and combination therapies

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP2277532A1 (en) 2002-09-11 2011-01-26 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
CA2537055A1 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
JP2008544746A (ja) 2005-05-12 2008-12-11 ザイモジェネティクス， インコーポレイテッド 免疫応答を調節するための組成物および方法
CA2654712C (en) 2006-06-06 2015-05-05 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
HUE036780T2 (hu) 2008-04-09 2018-07-30 Genentech Inc Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
PL2542590T5 (pl) 2010-03-05 2020-08-10 The Johns Hopkins University Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych
JP2015516980A (ja) 2012-04-26 2015-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３７抗体とベンダムスチンとの併用
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
EP2858673A4 (en) 2012-06-06 2016-06-22 Oncomed Pharm Inc BONDING AGENT FOR MODULATING THE HIPPO PATH AND USES THEREOF
WO2014105810A1 (en) 2012-12-24 2014-07-03 Abbvie Inc. Prolactin receptor binding proteins and uses thereof
KR20160030936A (ko) 2013-07-16 2016-03-21 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
BR112016003532A8 (pt) 2013-08-22 2018-01-30 Council Queensland Inst Medical Res modulação imunorreceptora para tratar o cancer e as infecções virais
US10966998B2 (en) 2013-09-05 2021-04-06 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
US10501737B2 (en) * 2013-09-30 2019-12-10 Chugai Seiyaku Kabushiki Kaisha Method for producing antigen-binding molecule using modified helper phage
BR112016020919A2 (pt) 2014-03-12 2018-01-23 Yeda Res & Dev redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc
EP3119913B1 (en) 2014-03-21 2021-01-06 The Brigham and Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
CN106459954A (zh) 2014-05-13 2017-02-22 中外制药株式会社 用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子
CN105233291A (zh) 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
MA40437A (fr) 2014-07-16 2017-05-24 Hoffmann La Roche Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
SG11201701161QA (en) 2014-08-19 2017-03-30 Merck Sharp & Dohme Anti-tigit antibodies
JP6877339B2 (ja) 2014-10-14 2021-05-26 ノバルティス アーゲー Ｐｄ−ｌ１に対する抗体分子およびその使用
CA3003133C (en) 2014-10-24 2020-09-15 StemImmune, Incorporated Combination immunotherapy approach for treatment of cancer
WO2016073282A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
MA40662B1 (fr) 2014-12-23 2020-12-31 Bristol Myers Squibb Co Anticorps contre tigit
EP3273944B1 (en) 2015-03-25 2024-11-20 The Regents of The University of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2016180781A1 (en) 2015-05-08 2016-11-17 Michele Maio Combination therapy of mesothelioma
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
KR20180021833A (ko) 2015-06-29 2018-03-05 더 락커펠러 유니버시티 증진된 효능제 활성을 갖는 cd40에 대한 항체
AU2016303485A1 (en) 2015-07-31 2018-03-01 Tarveda Therapeutics, Inc. Compositions and methods for immunomodulation
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CN115925931A (zh) 2015-08-14 2023-04-07 默沙东公司 抗tigit抗体
WO2017040790A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
CN108137691B (zh) 2015-09-02 2021-10-19 耶路撒冷希伯来大学伊萨姆研究发展有限公司 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
US20180251548A1 (en) 2015-09-14 2018-09-06 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-beta
NZ739750A (en) 2015-09-25 2019-11-29 Genentech Inc Anti-tigit antibodies and methods of use
PT3356413T (pt) 2015-10-01 2022-04-04 Potenza Therapeutics Inc Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas
KR20180084772A (ko) 2015-10-08 2018-07-25 마크로제닉스, 인크. 암 치료를 위한 조합 치료법
US10421810B2 (en) 2015-10-09 2019-09-24 Lentigen Technology, Inc. Chimeric antigen receptors and methods of use
CN109069624A (zh) 2016-01-15 2018-12-21 瑞美控股有限责任公司 癌症的免疫治疗
BR112018067458A2 (pt) 2016-03-04 2019-01-02 Abmuno Therapeutics Llc anticorpos para tigit
WO2017218970A1 (en) 2016-06-17 2017-12-21 Varian Medical Systems, Inc. Immune modulators in combination with radiation treatment
US12257352B2 (en) 2016-06-20 2025-03-25 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
KR20230145510A (ko) 2016-08-17 2023-10-17 컴퓨젠 엘티디. 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
MX2019002925A (es) 2016-09-15 2019-09-05 Idera Pharmaceuticals Inc Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.
CN110662552A (zh) 2016-11-30 2020-01-07 昂科梅德制药有限公司 包含tigit结合剂的癌症治疗方法
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
US10537637B2 (en) 2017-01-05 2020-01-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
SG11201907278VA (en) 2017-02-28 2019-09-27 Seattle Genetics Inc Anti-tigit antibodies
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
WO2018204363A1 (en) 2017-05-01 2018-11-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof
MA50661A (fr) 2017-05-02 2020-08-05 Merck Sharp & Dohme Formulations stables d'anticorps anti-tigit seuls et en association avec des anticorps du récepteur de mort programmée 1 (pd-1) et leurs procédés d'utilisation
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
IL272227B2 (en) 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
AU2018315432A1 (en) 2017-08-11 2020-03-26 Blink Biomedical Sas CD96-binding agents as immunomodulators
CN111051347B (zh) 2017-09-29 2021-12-21 江苏恒瑞医药股份有限公司 Tigit抗体、其抗原结合片段及医药用途
CN110914304B (zh) 2017-11-10 2022-07-26 江苏恒瑞医药股份有限公司 Cd96抗体、其抗原结合片段及医药用途
SG11202004158QA (en) 2017-12-28 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against tigit
TWI816729B (zh) 2017-12-30 2023-10-01 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
TW201932489A (zh) 2018-01-15 2019-08-16 大陸商南京傳奇生物科技有限公司 針對ｔｉｇｉｔ之抗體及其變異體
WO2019152574A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
SG11202004521QA (en) 2018-02-06 2020-06-29 I Mab Biopharma Us Ltd Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
KR20200135313A (ko) 2018-02-26 2020-12-02 제넨테크, 인크. 항-tigit 및 항-pd-l1 길항제 항체에 의한 치료를 위한 투약
MX2020008795A (es) 2018-02-28 2020-10-08 Yuhan Corp Anti cuerpos anti tigit y usos de los mismos.
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
SG11202104120VA (en) * 2018-10-31 2021-05-28 Delinia Inc Multivalent regulatory t cell modulators
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
EP3938396A1 (en) * 2019-03-11 2022-01-19 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
TWI760751B (zh) 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit及pd-1/tigit-結合分子
CA3144617A1 (en) * 2019-06-26 2020-12-30 Ap Biosciences, Inc. Antibodies for t-cell activation
MX2022002315A (es) 2019-08-30 2022-03-25 Agenus Inc Anticuerpos anti-cd96 y sus metodos de uso.
TW202304965A (zh) 2021-05-04 2023-02-01 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法
BR112023022367A2 (pt) * 2021-05-04 2024-02-20 Agenus Inc Anticorpos anti-tigit e métodos de uso dos mesmos

Also Published As

Publication number Publication date
PE20240369A1 (es) 2024-03-04
WO2022236276A2 (en) 2022-11-10
IL308157A (en) 2024-01-01
US12479913B2 (en) 2025-11-25
US20230014036A1 (en) 2023-01-19
AU2022271331A1 (en) 2023-10-26
US11718669B2 (en) 2023-08-08
JP2024516843A (ja) 2024-04-17
WO2022236276A3 (en) 2023-01-19
AU2022271331A9 (en) 2023-11-09
CO2023016037A2 (es) 2023-11-30
BR112023022319A2 (pt) 2024-02-20
CN117425494A (zh) 2024-01-19
AR125753A1 (es) 2023-08-09
CA3217289A1 (en) 2022-11-10
US20240141039A1 (en) 2024-05-02
KR20240006054A (ko) 2024-01-12
TW202304965A (zh) 2023-02-01
EP4333893A2 (en) 2024-03-13
CL2023003244A1 (es) 2024-04-19
EP4333893A4 (en) 2025-06-18

Similar Documents

Publication Publication Date Title
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
PH12020551907A1 (en) Antagonizing cd73 antibody
SA522432139B1 (ar) بروتينات ربط متعددة الخصوصية لمعالجة السرطان
PH12020551317A1 (en) Anti-cd73 antibodies and methods of use thereof
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
EA202090817A1 (ru) Триспецифические белки и способы их применения
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
NZ754051A (en) Novel antibodies and uses thereof
BR112017010110A2 (pt) anticorpos contra cd73 e usos do mesmo
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
PH12022550460A1 (en) Anti-cd96 antibodies and methods of use thereof
PH12019500571A1 (en) Anti-pd-1 antibodies
EA201590986A1 (ru) Антитела к ceacam5 и их применения
MY200710A (en) Novel fusion protein specific for cd137 and pd-l1
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
ZA202110285B (en) Antibodies and methods of use
MX2023013078A (es) Anticuerpos de inmunorreceptor de celulas t con dominios ig e itim (anti-tigit), anticuerpos de cumulo de diferenciacion 96 (anti-cd96) y metodos de uso de estos.
WO2020070678A3 (en) Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
BR112023022367A2 (pt) Anticorpos anti-tigit e métodos de uso dos mesmos
MX2024003615A (es) Anticuerpos que se unen al cumulo de diferenciacion 30 (cd30) y al cumulo de diferenciacion 3 (cd3).
WO2021043810A8 (en) Anti-fucosyl-gm1 antibodies
EA202092928A1 (ru) Dll3-cd3 биспецифические антитела